These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 27489350

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
    Wei Y, Lin S, Zhi W, Chu T, Liu B, Peng T, Xu M, Ding W, Cao C, Wu P.
    J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
    Chen F, Liu J, Song X, DuCote TJ, Byrd AL, Wang C, Brainson CF.
    Cancer Lett; 2022 Jan 01; 524():151-160. PubMed ID: 34655667
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer.
    Jiang W, Ouyang X, Li C, Long Y, Chen W, Ji Z, Shen X, Xiang L, Yang H.
    Immunology; 2023 Nov 01; 170(3):419-438. PubMed ID: 37469254
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
    Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R.
    Oncotarget; 2016 Nov 22; 7(47):76374-76389. PubMed ID: 27823983
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R.
    J Clin Oncol; 2012 Mar 10; 30(8):777-82. PubMed ID: 22271473
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
    Huang T, Ren K, Ding G, Yang L, Wen Y, Peng B, Wang G, Wang Z.
    Oncol Rep; 2020 Jun 10; 43(6):1906-1914. PubMed ID: 32186774
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.